

Mouse Monoclonal anti-HIF-2 alpha (ep190b), Sample Size

Catalog Number:	NB100-132SS
Background:	<p>Hypoxia contributes significantly to the pathophysiology of major categories of human disease, including myocardial and cerebral ischemia, cancer, pulmonary hypertension, congenital heart disease and chronic obstructive pulmonary disease.</p> <p>HIF-2 alpha is predominantly expressed in highly vascularized tissues of adult humans and endothelial cells of the embryonic and adult mouse, whereas HIF-1 alpha functions primarily in extravascular tissues. HIF-2 alpha is also a potent activator of the tie-2 gene, which is known to be selectively expressed in endothelial cells.</p>
Alternate Names:	anti-Endothelial pas domain protein 1 antibody, anti-Hif2a antibody, anti-Hypoxia inducible factor 2 alpha subunit antibody, anti-Member of pas superfamily 2 antibody, anti-MOP2 antibody, anti-EPAS1 antibody, anti-Hif-2a antibody, anti-Hif 2a antibody, anti-Hif 2 alpha antibody
Host:	Mouse
Research Areas:	Cancer Research, Hypoxia Inducible Factors and Prolyl-Hydroxylases, IHC Grade
Immunogen:	Human HIF-2 alpha amino acids 535-631.
Clone:	ep190b
Isotype:	IgG1
Specificity:	This antibody is specific for HIF-2 alpha and does not cross-react with HIF-1 alpha.
Species Reactivity:	NB 100-132 reacts with human and rat HIF-2 alpha. Ability to use in mouse is mixed with some positive and some negative results. Other species have not been tested.
Uses:	Western Blot (recognizes a band at ~118 kDa representing HIF-2 alpha) * Other applications have not been tested.
Dilutions:	Suggested working dilutions * immunohistochemistry 1:150-1:300, Western Blot 1:1000, * Investigator should determine optimal working dilutions.
Packaging:	0.025 ml protein G purified Mouse ascites.
Concentration:	1.6 mg/ml
Buffer:	PBS
Preservative:	0.05% Na azide
Storage:	Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles.
Limitations:	This product is for research use only and is not approved for use in humans or in clinical diagnosis. This product is guaranteed for 6 months from date of receipt.
Novus Specific References:	1. Bernhardt, W. M., et al. (2007) Involvement of Hypoxia-Inducible Transcription

- Factors in Polycystic Kidney Disease, 170, 830-842.
2. Grabmaier, K., et al. Strict regulation of CAIXG250/MN by HIF-1 alpha in clear cell renal cell carcinoma. *Oncogene*. 23: 5624-5631, 2004. 23: 4975-4983, 2004.
 3. Harvey, A.J., et al. Oxygen-Regulated Gene Expression in Bovine Blastocysts. *Biol. Reprod.* 71: 1108-1119.
 4. Koike, T., et al. Hypoxia induces adhesion molecules on cancer cells: A missing link between Warburg effect and induction of selectin-ligand carbohydrates. *PNAS*. 101:8132-8137, 2004.
 5. Koizume, S., et al. (2006) Activation of Cancer Cell Migration and Invasion by Ectopic Synthesis of Coagulation Factor VII, 66, 9453-9460.
 6. Li, L., et al. Evaluating Hypoxia-Inducible Factors-1alpha as a Cancer Therapeutic Target via Inducible RNA Interference In vivo. *American Association for Cancer Research* 65, 7249-7258, 2005.
 7. Mekhail, K., et al. HIF activation by pH-dependent nucleolar sequestration of VHL. *Nature Cell Biology*. 6: 642-647, 2004.
 8. Mohan, S., et al. von Hippel-Lindau protein complex is regulated by cell density. *Oncogene*. 22: 5270-5280, 2003.
 9. Nakamura, E., et al. Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein. *Am. J. Pathol.* 168:574-584, 2006.
 10. Pan, Y., et al. p53 cannot be induced by hypoxia alone but responds to the hypoxic microenvironment. *Oncogene*.
 11. Rathmell, W., et al. In Vitro and In Vivo Models Analyzing von Hippel-Lindau Disease-Specific Mutations. *Cancer Research*. 64: 8595-8603, 2004.
 12. Shinjima, Toshiaki, et al. Cancer Biology: Renal cancer cells lacking hypoxia inducible factor (HIF)-1a expression maintain vascular endothelial growth factor expression through HIF-2a. *Carcinogenesis*. 10.1093/carcin/bgl143, 2006
 13. van Patot, M.C., et al. Greater vascularity, lowered HIF-1/DNA binding, and elevated GSH as markers of adaptation to in vivo chronic hypoxia. *Am J Physiol Lung Cell Mol Physiol*. 287: 525-532, 2004.
 14. Xia G, et al. (2002) Positive expression of HIF-2alpha/ EPAS1 in invasive bladder cancer, 59(5): 774-778.
 15. Yan, Q., et al. (2007) The Hypoxia-Inducible Factor 2{alpha} N-Terminal and C-Terminal Transactivation Domains Cooperate To Promote Renal Tumorigenesis In Vivo, 27: 2092-2102.
 16. Yoshimura, H., et al. Prognostic Impact of Hypoxia-Inducible Factors 1 alpha and 2 alpha in Colorectal Cancer Patients: Correlation with Tumor Angiogenesis and Cyclooxygenase-2 Expression. *Clin. Caancer Res.* 10: 8554-8560, 2004.
 17. Zheng, X., et al. (2006) Cell-Type-Specific Regulation of Degradation of Hypoxia-Inducible Factor 1{alpha}: Role of Subcellular Compartmentalization, 26, 4628-4641.
 18. Zimmer, M., et al. Inhibition of Hypoxia-Inducible Factor Is Sufficient for Growth Suppression of VHL-/- Tumors. *Molecular Cancer Research*. 2: 89-95, 2004.
 19. Koizume, Shiro., et al. *Molecular Biology, Pathobiology, and Genetics: Activation of Cancer cell Migration and Invasion by Ectopic Synthesis fo Coagulation Factor VII.* 66: 9453-9460, 2006.
 20. Carroll, Patrick A., et al. *Virus-Cell Interactions: Latent Kaposi's Sarcoma-Associated Herpesvirus Infection of Endothelial Cells Activates Hypoxia-Induced Factors.* 80: 10802-10812, 2006
 21. Sutphin, P.D., et al. *Tageting the Loss of the von Hippel-Lindau Tumor Suppressor*

- Gene in Renal Cell Carcinoma Cells. *Cancer Res.* 2007 67: 5896-5905.
22. Koukourakis, M., *Cancer Research.* 61:1830-1832, 2001. (Immunohistochemistry)
 23. Blancher, C., et al. *Cancer Research.* 60: 7106-7113, 2000. (Western Blot and Immunohistochemistry)
 24. Talks, K.L. and Turley, H. *Amer. J. of Pathology.* 157: 411-421, 2000. (Western Blot and Immunocytochemistry)
 25. Giatromanolaki, A., et al. Expression of hypoxia-inducible Carbonic Anhydrase-9 Relates to Angiogenic Pathways and Independently to poor Outcome in Non-Small Cell Lung Cancer. *Cancer Research.* 2001;61:7992-7998.
 26. Martin-Puig, S., et al. Role of Iron (II)-2-Oxoglutarate-dependent Dioxygenases in the Generation of Hypoxia-induced Phosphatidic Acid through HIF-1/2 and von Hippel-Lindau-independent Mechanisms. *Journal of Biological Chemistry.* 2004; 279(10):9504-9511.
 27. Kubo T, Sugita T, Shimose S, Matsuo T, Arihiro K, Ochi M. Expression of hypoxia-inducible factor-1{alpha} and its relationship to tumour angiogenesis and cell proliferation in cartilage tumours. *J Bone Joint Surg Br.* March 1, 2008;90-B(3):364-70. (WB)
 28. Chintalapudi MR, Markiewicz M, Kose N, et al. Cyr61/CCN1 and CTGF/CCN2 mediate the proangiogenic activity of VHL-mutant renal carcinoma cells. *Carcinogenesis.* April 1, 2008;29(4):696-703.

General References:

These references discuss the use of this clone but not using this particular antibody production.

1. Wiesener, M., Turley, H., Allen, W., Willam, C., Eckardt, K-U., Talks, K., Wood, S., Gatter, K., Harris, A., Pugh, C., Ratcliffe, P., and P. Maxwell. Induction of Endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1 alpha. *Blood.* 92: 2260-2268, 1998. (Original reference using this clone)
2. Koukourakis, M., *Cancer Research.* 61:1830-1832, 2001. (Immunohistochemistry)
3. Blancher, C., et al. *Cancer Research.* 60: 7106-7113, 2000. (Western Blot and Immunohistochemistry)
4. Talks, K.L. and Turley, H. *Amer. J. of Pathology.* 157: 411-421, 2000. (Western Blot and Immunocytochemistry)
5. Giatromanolaki, A., et al. Expression of hypoxia-inducible Carbonic Anhydrase-9 Relates to Angiogenic Pathways and Independently to poor Outcome in Non-Small Cell Lung Cancer. *Cancer Research.* 61:7992-7998, 2001.
6. Martin-Puig, S., et al. Role of Iron (II)-2-Oxoglutarate-dependent Dioxygenases in the Generation of Hypoxia-induced Phosphatidic Acid through HIF-1/2 and von Hippel-Lindau-independent Mechanisms. *Journal of Biological Chemistry.* 279(10):9504-9511, 2004.

Gene Id: 2034
Gene System: EPAS1
Reference Sequence: Q99814